Glyxambi is a fixed-dose combination of sodium-glucose cotransporter-2 inhibitor Jardiance (empagliflozin; Boehringer Ingelheim/Eli Lilly) and dipeptidyl peptidase-IV inhibitor Tradjenta (linagliptin; Boehringer Ingelheim/Eli Lilly). Both linagliptin and empagliflozin were originally developed by Boehringer Ingelheim. Under the terms of the partnership between Boehringer Ingelheim and Eli Lilly, Glyxambi revenues across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) will be shared equally between the two companies.
Glyxambi first launched in the US in 2015. Two dosages are available: a 25mg empagliflozin + 5mg linagliptin tablet, and a 10mg empagliflozin + 5mg linagliptin tablet.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Glyxambi : Diabetes type 2
LIST OF FIGURES 7 Figure 1: Glyxambi for type 2 diabetes – SWOT analysis
8 Figure 2: Datamonitor Healthcare drug assessment scorecard for Glyxambi compared to Januvia
9 Figure 3: Datamonitor Healthcare drug assessment scorecard for Glyxambi compared to Januvia
LIST OF TABLES 5 Table 1: Glyxambi drug profile
6 Table 2: Overview of pivotal trial data for Glyxambi in diabetes
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.